drugset
drugset / Trial / NCT01336244

GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study

NCT01336244 ↗

Phase 1 Completed 45 enrolled Lakefront Biotherapeutics NV
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses (MAD) of GLPG0778 given to healthy subjects for 13 days compared to placebo, and to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0778 after multiple oral administrations.

Timeline

Start
2011-04
Primary completion
2011-08
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SOLCITINIB Small molecule 50 mg Oral
Subject SOLCITINIB Small molecule 100 mg Oral

Indications

No indication recorded.